With the advancement of scientific research and development, the pharmaceutical and biotechnology industry has seen new technologies that allow more effective and safer drugs to be developed. The advent of computers has accelerated scientific progress by providing the ability to read and modify the design of tiny particles like cells and even more, DNA.
The power to modify the basic building blocks of organisms like cells and DNA led to the development of synthetic biology – the creation of artificial versions of naturally occurring biological things found in nature. Some companies involved in the development of synthetic biology drug candidates include Codexis CDXS, Precigen PGEN and Therapeutic Verve VERV.
According to the National Human Genome Research Institute, the scientific field that deals with the engineering of organisms is called synthetic biology. Scientists redesign a particular organism, creating new abilities to solve problems in medicine, manufacturing and agriculture.
Examples of synthetic biology are available in all industries. Redesigning microorganisms to eliminate pollution, modifying rice to enrich it with nutrients or modifying bacteria to treat cancer are all examples of synthetic biology. These changes are made by altering the genomic code of an organism.
In the field of biotechnology, people tend to confuse synthetic biology with genome editing. Synthetic biology can be different from genome editing in the way changes are made. As scientists assemble an organism’s DNA and insert it into their subject organism to alter its properties in synthetic biology processes, genome editing involves smaller changes in the organism’s own DNA.
Synthetic biology researchers developed the poliovirus from scratch using DNA modification technologies in 2002 and the first synthetic bacterial genome was completed in 2008. Although there are concerns related to the environmental impacts of the The introduction of modified organisms into the ecosystem, such as biological weapons and synthetic biology, has progressed well over the past decade. The field will continue to progress as it has the potential to accelerate the development of effective and safe therapies.
Here we discuss three committed actions in the field of scientific biology that investors should follow as they have the potential to generate wealth for them in the future. Each of these actions carries a Zacks Rank # 3 (Hold). You can see The full list of Zacks # 1 Rank (Strong Buy) stocks today here.
Codexis is engaged in the discovery, development and commercialization of modified enzymes which are used by its partners to develop effective drugs. The company also grants rights to its proprietary CodeEvolver protein engineering technology platform to global pharmaceutical companies for enzyme development. Codexis has collaborations with popular pharmaceutical companies, including Novartis, granting them rights to CodeEvolver.
Codexis is also developing biotherapeutic drug candidates targeting new opportunities. The company is developing drug candidates in collaboration with NestlÃ© for the treatment of PKU and with Takeda for the treatment of Fabry disease, Pompe disease and undisclosed blood factor deficiency.
The company can develop new therapies and enter into new collaborative agreements by leveraging its technology platform. The successful development of new products in partnership as well as new partnership agreements will boost the Codexis stock in 2022.
Codexis shares have jumped 53% so far this year. Zacks’ Consensus Estimate for Codexis Loss Per Share (EPS) 2022 has increased 3.9% over the past 30 days.
Codexis Prize, Inc.
Codexis, Inc. Awards | Quote from Codexis, Inc.
Precigen is a synthetic biology company focused on the development of the next generation of gene and cell therapies targeting immuno-oncology, autoimmune diseases and infectious diseases. The company is developing six pipeline candidates in early stage clinical studies.
Candidates are targeting different cancer indications including acute myeloid leukemia, ovarian cancer and rare diseases positive for human papillomavirus such as myelodysplastic syndromes and type I diabetes mellitus. Targeted indications represent significant opportunities . Positive clinical updates will be a key catalyst for Precigen’s stock in 2022.
Zacks’ consensus estimate for Precigen’s loss per share in 2022 has declined 1.7% in the past 30 days.
Precigen, Inc. Award | Estimate Precigen, Inc.
Verve Therapeutics is focused on the development of single course genetic therapies for the treatment of cardiovascular disease. The company has two preclinical programs targeting genes that control blood lipids such as low density lipoprotein (LDL-C) cholesterol. VERV believes that its therapies have the potential to provide lasting benefits throughout a patient’s life.
Verve Therapeutics completed its initial public offering (âIPOâ) in June 2021. The company’s targeted indications represent significant opportunities. Updates related to the advancement of pipeline candidates to clinical stage development will be a key driver for Verve Therapeutics’ stock in 2022.
The title has gained 29.5% since its IPO. Zacks ‘consensus estimate for Verve Therapeutics’ loss per share in 2022 has remained unchanged for the past 30 days.
Verve Therapeutics, Inc.
Verve Therapeutics, Inc. Price | Quote from Verve Therapeutics, Inc.
Zacks Top 10 stocks for 2022
In addition to the investment ideas discussed above, would you like to know our top 10 picks for all of 2022?
From its creation in 2012 until November, the Top 10 Zacks stocks gained an impressive + 962.5% versus + 329.4% for the S&P 500. Now our research director combs through the 4,000 companies covered by the Zacks rankings to select the top 10 tickers to buy and hold . Don’t miss your chance to participate in these actions when they release on January 3.
Be the first to access the new Top 10 stocks >>
Click to get this free report
Codexis, Inc. (CDXS): Free Stock Analysis Report
Precigen, Inc. (PGEN): Free Inventory Analysis Report
Verve Therapeutics, Inc. (VERV): Free Inventory Analysis Report
To read this article on Zacks.com, click here.
Zacks investment research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.